Paper36911456
Successful Rapid Desensitization of a Pediatric Multiple Sclerosis Patient with Anaphylaxis to Ocrelizumab.
Karaaslan HBG and 7 others. Ann Indian Acad Neurol, 2022. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Successful Rapid Desensitization of a Pediatric Multiple Sclerosis Patient with Anaphylaxis to Ocrelizumab. Papers, record 36911456. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36911456
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Successful Rapid Desensitization of a Pediatric Multiple Sclerosis Patient with Anaphylaxis to Ocrelizumab.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References9
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 25754718 | Hypersensitivity to biological agents-updated diagnosis, management, and treatment. | J Allergy Clin Immunol Pract | 2015 | https://conductscience.org/library/papers/25754718 | PubMed |
| 2 | 29275977 | Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. | Lancet Neurol | 2018 | https://conductscience.org/library/papers/29275977 | PubMed |
| 3 | 35222433 | Case Report: Rapid Desensitization to Ocrelizumab for Multiple Sclerosis Is Effective and Safe. | Front Immunol | 2022 | https://conductscience.org/library/papers/35222433 | PubMed |
| 4 | 33202059 | Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO. | Br J Clin Pharmacol | 2021 | https://conductscience.org/library/papers/33202059 | PubMed |
| 5 | 30844611 | Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. | Mult Scler Relat Disord | 2019 | https://conductscience.org/library/papers/30844611 | PubMed |
| 6 | 15316518 | Clinical features and severity grading of anaphylaxis. | J Allergy Clin Immunol | 2004 | https://conductscience.org/library/papers/15316518 | PubMed |
| 7 | 33224101 | B Cells in Multiple Sclerosis and Virus-Induced Neuroinflammation. | Front Neurol | 2020 | https://conductscience.org/library/papers/33224101 | PubMed |
| 8 | 32496608 | Medical algorithm: Diagnosis and treatment of drug hypersensitivity reactions to biologicals. | Allergy | 2020 | https://conductscience.org/library/papers/32496608 | PubMed |
| 9 | 29518427 | Hypersensitivity reactions to therapeutic monoclonal antibodies: Phenotypes and endotypes. | J Allergy Clin Immunol | 2018 | https://conductscience.org/library/papers/29518427 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| IGHE | 3497 | PubTator's text mining | https://conductscience.org/library/genes/3497 | NCBI Gene |
| KRT20 | 54474 | PubTator's text mining | https://conductscience.org/library/genes/54474 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36911456
GET https://conductscience.org/api/papers/v1/36911456/authors